Antimalarial activity of KAF156 in falciparum and vivax malaria

Antimalarial activity of KAF156 in falciparum and vivax malaria

<strong>Background:</strong> KAF156 belongs to a new class of antimalarials (imidazolopiperazines), with activity against asexual and sexual blood stages and the pre-erythrocytic liver stages of malaria parasites. <strong>Methods:</strong> We conducted a phase 2, open-label,...

Bibliográfalaš dieđut
Váldodahkkit:	Nosten, F, White, N, Phyo, A, Thanh, D, Uthaisin, C, Hanboonkunupakarn, B, Pukrittayakamee, S, Jittamala, P, Chuthasmit, K, Cheung, M, Feng, Y, Li, R, Magnusson, B, Sultan, M, Wieser, D, Xun, X, Zhao, R, Diagana, T, Pertel, P, Leong, F
Materiálatiipa:	Journal article
Almmustuhtton:	Massachusetts Medical Society 2016

Geahča maid

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.
Dahkki: Kuhen, K, et al.
Almmustuhtton: (2014)

Spiroindolone KAE609 for falciparum and vivax malaria.
Dahkki: White, N, et al.
Almmustuhtton: (2014)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Dahkki: Phyo, A, et al.
Almmustuhtton: (2016)

Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (2004)

Antimalarial effects of rifampin in Plasmodium vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (1994)

Therapeutic responses to different antimalarial drugs in vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (2000)

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand.
Dahkki: Tarning, J, et al.
Almmustuhtton: (2014)

Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with plasmodium vivax malaria in Thailand
Dahkki: Tarning, J, et al.
Almmustuhtton: (2014)

Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (1994)

Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (2008)

Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs
Dahkki: Chairat, K, et al.
Almmustuhtton: (2018)

The threat of antimalarial drug resistance
Dahkki: Hanboonkunupakarn, B, et al.
Almmustuhtton: (2016)

In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand.
Dahkki: Chotivanich, K, et al.
Almmustuhtton: (2004)

Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity.
Dahkki: Russell, B, et al.
Almmustuhtton: (2013)

Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea.
Dahkki: Chotivanich, K, et al.
Almmustuhtton: (2009)

Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.
Dahkki: Douglas, N, et al.
Almmustuhtton: (2011)

Nuclear orientation of156Tb in gadolinium matrix
Dahkki: Říkovská, J, et al.
Almmustuhtton: (1979)

A systematic overview of published antimalarial drug trials.
Dahkki: Myint, H, et al.
Almmustuhtton: (2004)

Plasmodium vivax susceptibility to ferroquine.
Dahkki: Leimanis, M, et al.
Almmustuhtton: (2010)

Mode of action and features of antimalarial drugs
Dahkki: Nosten, F, et al.
Almmustuhtton: (1999)

Mode of action and features of antimalarial drugs.
Dahkki: Nosten, F, et al.
Almmustuhtton: (1999)

Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study.
Dahkki: Mcgready, R, et al.
Almmustuhtton: (2012)

Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: A population-based study
Dahkki: McGready, R, et al.
Almmustuhtton: (2012)

Epidemiology of Plasmodium vivax malaria infection in Nepal
Dahkki: Rijal, KR, et al.
Almmustuhtton: (2018)

New antimalarials. A risk-benefit analysis.
Dahkki: Nosten, F, et al.
Almmustuhtton: (1995)

Low-energy structure of isotopes 152-156Sm
Dahkki: Rosly, Noora, et al.
Almmustuhtton: (2012)

Antimalarial drugs in pregnancy: a review.
Dahkki: Nosten, F, et al.
Almmustuhtton: (2006)

Pulmonary oedema in vivax malaria.
Dahkki: Pukrittayakamee, S, et al.
Almmustuhtton: (1998)

Rosetting responses of Plasmodium-infected erythrocytes to antimalarials
Dahkki: Lee, W-C, et al.
Almmustuhtton: (2022)

Artemisinin combination therapy for vivax malaria.
Dahkki: Douglas, N, et al.
Almmustuhtton: (2010)

L4 F739 (146-156) [fotograf udara]
Dahkki: Malaysia. Direktorat Pemetaan Negara

L5 F800 (156-181) [fotograf udara]
Dahkki: Malaysia. Direktorat Pemetaan Negara

L20S F3 (138-156) [fotograf udara]

L72S C81 (156-185) [fotograf udara]

L59S C110 (138-156) [fotograf udara]

L4-S C40 (147-156) [fotograf udara]

Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs.
Dahkki: Supanaranond, W, et al.
Almmustuhtton: (1993)

Rosette formation by Plasmodium vivax.
Dahkki: Udomsanpetch, R, et al.
Almmustuhtton: (1995)

Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax.
Dahkki: Imwong, M, et al.
Almmustuhtton: (2011)

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults
Dahkki: Hanboonkunupakarn, B, et al.
Almmustuhtton: (2024)